Associate Professor Lenka Munoz
Lab Head, Charles Perkins Centre, School of Medical Sciences, University of Sydney
Glioblastoma is the most aggressive primary brain tumour with median patient survival of 15 months. Given the extensive intratumoural molecular heterogeneity of glioblastomas and the lack of molecularly-targeted drugs that can permeate the blood-brain barrier, glioblastoma remains a major unmet medical need. I will present recent data from my laboratory into the development of blood-brain barrier permeable cancer drugs, and will specifically focus on the investigations to delineate the mechanism of action of drugs targeting kinases, microtubules and epigenetic enzymes.
Lenka Munoz received a PhD in Medicinal Chemistry from the University of Bonn, Germany. Her post-doctoral training in molecular pharmacology was at the Northwestern University, USA. She is an Associate Professor and Laboratory Head at The University of Sydney, Australia. Her research focuses on understanding the molecular mechanism of action of kinase inhibitors in cancer models and developing effective therapies for glioblastoma. Recent work includes publications in Nature Reviews Drug Discovery, Cancer Cell, Journal of Medicinal Chemistry, Biochemical Pharmacology, Oncogene and Cell Death Discovery. She also has a substantial intellectual property and out-licencing portfolio around neuro-oncology therapeutics that she has developed.
For more information on Associate Professor Lenka Munoz.
Download the poster here.